AIM:RENE

Stock Analysis Report

Executive Summary

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom.


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has ReNeuron Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RENE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

31.3%

RENE

-2.5%

GB Biotechs

1.7%

GB Market


1 Year Return

-41.4%

RENE

2.8%

GB Biotechs

-21.8%

GB Market

Return vs Industry: RENE underperformed the UK Biotechs industry which returned 3.6% over the past year.

Return vs Market: RENE underperformed the UK Market which returned -23.6% over the past year.


Shareholder returns

RENEIndustryMarket
7 Day31.3%-2.5%1.7%
30 Day16.1%-8.4%-12.0%
90 Day-8.1%-7.3%-25.3%
1 Year-41.4%-41.4%3.6%2.8%-17.9%-21.8%
3 Year-45.3%-45.3%2.6%1.0%-11.8%-22.8%
5 Year-64.1%-64.1%0.4%-1.6%0.1%-22.4%

Price Volatility Vs. Market

How volatile is ReNeuron Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ReNeuron Group undervalued compared to its fair value and its price relative to the market?

2.05x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RENE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RENE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RENE is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: RENE is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RENE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RENE is good value based on its PB Ratio (2x) compared to the GB Biotechs industry average (2.7x).


Next Steps

Future Growth

How is ReNeuron Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

49.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RENE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RENE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RENE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RENE's revenue (46.1% per year) is forecast to grow faster than the UK market (2.5% per year).

High Growth Revenue: RENE's revenue (46.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RENE's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ReNeuron Group performed over the past 5 years?

-10.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RENE is currently unprofitable.

Growing Profit Margin: RENE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RENE is unprofitable, and losses have increased over the past 5 years at a rate of -10.6% per year.

Accelerating Growth: Unable to compare RENE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RENE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14.9%).


Return on Equity

High ROE: RENE has a negative Return on Equity (-63.43%), as it is currently unprofitable.


Next Steps

Financial Health

How is ReNeuron Group's financial position?


Financial Position Analysis

Short Term Liabilities: RENE's short term assets (£26.8M) exceed its short term liabilities (£7.2M).

Long Term Liabilities: RENE's short term assets (£26.8M) exceed its long term liabilities (£794.0K).


Debt to Equity History and Analysis

Debt Level: RENE is debt free.

Reducing Debt: RENE has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RENE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RENE has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -12.1% each year.


Next Steps

Dividend

What is ReNeuron Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RENE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RENE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RENE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RENE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RENE's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.3yrs

Average management tenure


CEO

Olav Hellebø (54yo)

5.58s

Tenure

UK£539,000

Compensation

Mr. Olav Hellebø, MBA, BBA, has been the Chief Executive Officer of ReNeuron Group plc since September 8, 2014. Mr. Hellebø served as an Executive of Aqualis ASA. He is a Co-Founder and Chairman of Palma B ...


CEO Compensation Analysis

Compensation vs Market: Olav's total compensation ($USD662.24K) is above average for companies of similar size in the UK market ($USD335.16K).

Compensation vs Earnings: Olav's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Olav Hellebø
CEO & Director5.58yrsUK£539.00k0.068% £28.1k
Michael Hunt
CFO, Company Secretary & Executive Director19.25yrsUK£344.00k0.094% £39.0k
Randolph Corteling
Head of Research5yrsno datano data
Richard Beckman
Chief Medical Officer2yrsno datano data

5.3yrs

Average Tenure

Experienced Management: RENE's management team is seasoned and experienced (5.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Olav Hellebø
CEO & Director5.58yrsUK£539.00k0.068% £28.1k
Michael Hunt
CFO, Company Secretary & Executive Director19.25yrsUK£344.00k0.094% £39.0k
John Berriman
Non-Executive Chairman5.08yrsUK£52.00k0.28% £117.6k
Claudia D'Augusta
Non-Executive Director2.58yrsUK£37.00kno data
Trevor Jones
Member of Scientific & Strategic Advisory Group7.83yrsUK£16.00kno data
Douglas Losordo
Member of Clinical Advisory Board10.17yrsno datano data
Jack Price
Member of Scientific and Strategic Advisory Groupno datano datano data
Simon Cartmell
Non-Executive Director8.75yrsUK£38.00k0.049% £20.3k
William Hiatt
Member of Clinical Advisory Board10.17yrsno datano data
Michael Owen
Chair of Scientific Advisory Board & Non-Executive Director4.33yrsUK£27.00k0.013% £5.5k

8.3yrs

Average Tenure

61yo

Average Age

Experienced Board: RENE's board of directors are considered experienced (8.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ReNeuron Group plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ReNeuron Group plc
  • Ticker: RENE
  • Exchange: AIM
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£41.384m
  • Shares outstanding: 31.83m
  • Website: https://www.reneuron.com

Number of Employees


Location

  • ReNeuron Group plc
  • Pencoed Business Park
  • Pencoed
  • CF35 5HY
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RENEAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPAug 2005
RQE1DB (Deutsche Boerse AG)YesOrdinary SharesDEEURAug 2005
RNUG.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDAug 2005
RENEAIM (London Stock Exchange AIM Market)ORD GBP0.01GBGBPJan 2018

Biography

ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in Phase IIb clinical trial for stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also developing CTX-derived exosomes, which are Nano-sized packages of information released by CTX cells. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/07 21:18
End of Day Share Price2020/04/07 00:00
Earnings2019/09/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.